gms | German Medical Science

71. Tagung der Vereinigung Norddeutscher Augenärzte

10. - 11.06.2022, Bremen

IVOM during COVID-19: was it possible to maintain the supply? HH Covid IVOM Study

Meeting Abstract

  • Joel Lüthy - Augenklinik Asklepios Nord-Heidberg, Hamburg
  • B. Stemplewitz - Augenklinik Asklepios Klinik Barmbek, Hamburg
  • M. Spitzer - Klinik und Poliklinik für Augenheilkunde Universitätsklinikums Hamburg-Eppendorf, Hamburg
  • M.T. Eddy - Augenklinik Asklepios Altona, Hamburg
  • U. Schaudig - Augenklinik Asklepios Klinik Barmbek, Hamburg
  • M. Schargus - Augenklinik Asklepios Nord-Heidberg, Hamburg

Vereinigung Norddeutscher Augenärzte. 71. Tagung der Vereinigung Norddeutscher Augenärzte (VNDA). Bremen, 10.-11.06.2022. Düsseldorf: German Medical Science GMS Publishing House; 2022. Doc22vnda25

doi: 10.3205/22vnda25, urn:nbn:de:0183-22vnda256

Veröffentlicht: 31. Oktober 2022

© 2022 Lüthy et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe



Purpose: This study aims to evaluate the impact of the first coronavirus 2019 (COVID-19) wave in 2020 on patients scheduled for intravitreal injections (IVI) in a German metropolitan region.

Methods: We performed a multicentre prospective survey and retrospective analysis of the records of patients treated with intravitreal injections during the 20-week period from March to July 2020 in all four hospital eye departments in the city of Hamburg using a questionnaire (on treatment adherence, SarsCoV2-related personal, familial and social data) and treatment data.

Results: A total of 1,038 patients (2,472 IVI, 1,231 eyes) and 818 questionnaires were evaluated. Longer duration of therapy, lower visual acuity (VA) of the treated and higher VA of the fellow untreated eye was were associated with a higher probability of visit cancellation. Every additional year of life posed a 2.6% lower risk of noncompliance. A COVID-19 infection in the family environment displayed a 5.5-fold chance of visit cancellation. Patients treated for neovascular age-related macular degeneration (nAMD) had a 36% reduced risk of visit cancellation compared to patients with diabetic macular oedema (DME).

Conclusion: A long preceding treatment period, low VA of the treated eye, high VA of the untreated eye, COVID-19 in the family and DME were identified as risk factors for IVI visit cancellations during the COVID-19 pandemic. Compliance to treatment might be improved in the future by taking these risk factors into account when scheduling patients for IVI during the exceptional circumstances of a pandemic.